SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide
the best opportunity for controlling transmission and protecting populations. Despite the …

The number of studies investigating the human gastrointestinal tract using various single-
cell profiling methods has increased substantially in the past few years. Although this …

The cumulative impact of chronic inflammation in patients with inflammatory bowel diseases
predisposes to the development of inflammatory bowel disease-associated colorectal …

Aza-2′-deoxycytidine (5-aza-dC) is a nucleoside analogue with cytotoxic and DNA
demethylating effects. Here we show that 5-aza-dC induces the proteasomal degradation of …

Objective IBD prevalence is estimated to be rising, but no detailed, recent UK data are
available. The last reported prevalence estimate in the UK was 0.40% in 2003. We aimed to …

Background Biologics and small molecules for inflammatory bowel disease (IBD) may
increase infection risk. Herpes zoster causes acute and long‐term symptoms, but …

Objective To determine the challenges in diagnosis, monitoring, support provision in the
management of inflammatory bowel disease (IBD) patients and explore the adaptations of …

Objective Management of acute severe UC (ASUC) during the novel COVID-19 pandemic
presents significant dilemmas. We aimed to provide COVID-19-specific guidance using …

Background There is a paucity of evidence to support safe and effective management of
patients with acute severe ulcerative colitis during the COVID-19 pandemic. We sought to …

Interleukin (IL)-17 and IL-23 are crucial for mediating gut mucosal inflammation in
inflammatory bowel disease (IBD), which has led to new therapeutic strategies. We …